{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:03:40Z","timestamp":1790222620345,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200894"],"award-info":[{"award-number":["82200894"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200894"],"award-info":[{"award-number":["82200894"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Foundation of Zhongshan Hospital Fudan University","award":["LCBSHZX013"],"award-info":[{"award-number":["LCBSHZX013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03595-1","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T12:02:12Z","timestamp":1706875332000},"page":"398-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Somatostatin receptor subtype 2A expression and genetics in 184 paragangliomas: a single center retrospective observational study"],"prefix":"10.1007","volume":"85","author":[{"given":"Yanting","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-8169","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"issue":"1","key":"3595_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"O. Mete, S.L. Asa, A.J. Gill et al. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33(1), 90\u2013114 (2022). https:\/\/doi.org\/10.1007\/s12022-022-09704-6","journal-title":"Endocr Pathol"},{"issue":"5","key":"3595_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1210\/jcem.74.5.1349024","volume":"74","author":"JC Reubi","year":"1992","unstructured":"J.C. Reubi, B. Waser, S. Khosla et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74(5), 1082\u20131089 (1992). https:\/\/doi.org\/10.1210\/jcem.74.5.1349024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3595_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"JC Reubi","year":"2003","unstructured":"J.C. Reubi, Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4), 389\u2013427 (2003). https:\/\/doi.org\/10.1210\/er.2002-0007","journal-title":"Endocr Rev"},{"issue":"1","key":"3595_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7150\/thno.77918","volume":"13","author":"M Ullrich","year":"2023","unstructured":"M. Ullrich, S. Richter, J. Liers et al. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models. Theranostics 13(1), 278\u2013294 (2023). https:\/\/doi.org\/10.7150\/thno.77918","journal-title":"Theranostics"},{"key":"3595_CR5","doi-asserted-by":"publisher","unstructured":"A. Fischer, S. Kloos, U. Maccio et al. Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics and therapeutic responses. J Clin Endocrinol Metab. dgad166 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad166","DOI":"10.1210\/clinem\/dgad166"},{"issue":"10","key":"3595_CR6","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"D. Ta\u00efeb, R.J. Hicks, E. Hindi\u00e9 et al. European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46(10), 2112\u20132137 (2019). https:\/\/doi.org\/10.1007\/s00259-019-04398-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3595_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"J.C. Reubi, J.C. Schar, B. Waser et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3), 273\u2013282 (2000). https:\/\/doi.org\/10.1007\/s002590050034","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"3595_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","volume":"36","author":"M Koerner","year":"2012","unstructured":"M. Koerner, B. Waser, A. Schonbrunn et al. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for In Vivo somatostatin receptor targeting. Am J Surg Pathol 36(2), 242\u2013252 (2012). https:\/\/doi.org\/10.1097\/PAS.0b013e31823d07f3","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"3595_CR9","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.Ccr-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"I. Janssen, E.M. Blanchet, K. Adams et al. Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 21(17), 3888\u20133895 (2015). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2751","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3595_CR10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.2967\/jnumed.116.187690","volume":"58","author":"I Janssen","year":"2017","unstructured":"I. Janssen, C.C. Chen, Z. Zhuang et al. Functional imaging signature of patients presenting with polycythemia\/paraganglioma syndromes. J Nucl Med 58(8), 1236\u20131242 (2017). https:\/\/doi.org\/10.2967\/jnumed.116.187690","journal-title":"J Nucl Med"},{"key":"3595_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","volume":"86","author":"H Leijon","year":"2019","unstructured":"H. Leijon, S. Remes, J. Hagstrom et al. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol 86, 66\u201375 (2019). https:\/\/doi.org\/10.1016\/j.humpath.2018.11.020","journal-title":"Hum Pathol"},{"issue":"1","key":"3595_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.beem.2016.01.001","volume":"30","author":"M Koerner","year":"2016","unstructured":"M. Koerner, Specific biology of neuroendocrine tumors: peptide receptors as molecular targets. Best Pract Res Clin Endocrinol Metab 30(1), 19\u201331 (2016). https:\/\/doi.org\/10.1016\/j.beem.2016.01.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"3595_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","volume":"46","author":"MS Elston","year":"2015","unstructured":"M.S. Elston, G.Y. Meyer-Rochow, H.M. Conaglen et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. Hum Pathol 46(3), 390\u2013396 (2015). https:\/\/doi.org\/10.1016\/j.humpath.2014.11.012","journal-title":"Hum Pathol"},{"key":"3595_CR14","doi-asserted-by":"publisher","first-page":"625312","DOI":"10.3389\/fendo.2021.625312","volume":"12","author":"M Patel","year":"2021","unstructured":"M. Patel, I. Tena, A. Jha et al. Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: old players in a new precision medicine world. Front Endocrinol (Lausanne) 12, 625312 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.625312","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"3595_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","volume":"62","author":"JA Carrasquillo","year":"2021","unstructured":"J.A. Carrasquillo, C.C. Chen, A. Jha et al. Imaging of pheochromocytoma and paraganglioma. J Nucl Med 62(8), 1033\u20131042 (2021). https:\/\/doi.org\/10.2967\/jnumed.120.259689","journal-title":"J Nucl Med"},{"issue":"11","key":"3595_CR16","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/erc-19-0165","volume":"26","author":"D Ta\u00efeb","year":"2019","unstructured":"D. Ta\u00efeb, A. Jha, G. Treglia et al. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer 26(11), R627\u2013R652 (2019). https:\/\/doi.org\/10.1530\/erc-19-0165","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"3595_CR17","doi-asserted-by":"publisher","first-page":"T135","DOI":"10.1530\/erc-15-0175","volume":"22","author":"F Castinetti","year":"2015","unstructured":"F. Castinetti, A. Kroiss, R. Kumar et al. Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer 22(4), T135\u2013T145 (2015). https:\/\/doi.org\/10.1530\/erc-15-0175","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"3595_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"S. N\u00f6lting, N. Bechmann, D. Taieb et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 43(2), 199\u2013239 (2022). https:\/\/doi.org\/10.1210\/endrev\/bnab019","journal-title":"Endocr Rev"},{"issue":"5","key":"3595_CR19","doi-asserted-by":"publisher","first-page":"E1835","DOI":"10.1210\/clinem\/dgac058","volume":"107","author":"J Zhang","year":"2022","unstructured":"J. Zhang, M. Li, Y. Pang et al. Genetic characteristics of incidental pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 107(5), E1835\u2013E1842 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac058","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3595_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"L. Fishbein, I. Leshchiner, V. Walter et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31(2), 181\u2013193 (2017). https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001","journal-title":"Cancer Cell"},{"issue":"10","key":"3595_CR21","doi-asserted-by":"publisher","first-page":"dgaa502","DOI":"10.1210\/clinem\/dgaa502","volume":"105","author":"J Jiang","year":"2020","unstructured":"J. Jiang, J. Zhang, Y. Pang et al. Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 105(10), dgaa502 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa502","journal-title":"J Clin Endocrinol Metab"},{"key":"3595_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1746-1596-8-9","volume":"8","author":"Y Shi","year":"2013","unstructured":"Y. Shi, D. He, Y. Hou et al. An alternative high output tissue microarray technique. Diagn Pathol. 8, 9 (2013). https:\/\/doi.org\/10.1186\/1746-1596-8-9","journal-title":"Diagn Pathol."},{"key":"3595_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000074662","volume":"31","author":"WW de Herder","year":"2004","unstructured":"W.W. de Herder, L.J. Hofland, Somatostatin receptors in pheochromocytoma. Front Horm Res 31, 145\u2013154 (2004). https:\/\/doi.org\/10.1159\/000074662","journal-title":"Front Horm Res"},{"issue":"52","key":"3595_CR24","doi-asserted-by":"publisher","first-page":"89958","DOI":"10.18632\/oncotarget.21194","volume":"8","author":"D Kaemmerer","year":"2017","unstructured":"D. Kaemmerer, J. S\u00e4nger, R. Arsenic et al. Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget 8(52), 89958\u201389969 (2017). https:\/\/doi.org\/10.18632\/oncotarget.21194","journal-title":"Oncotarget"},{"issue":"2","key":"3595_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/cen.13737","volume":"89","author":"M","year":"2018","unstructured":"M, L. Gild, N. Naik, J. Hoang et al. Role of DOTATATE-PET\/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf) 89(2), 139\u2013147 (2018). https:\/\/doi.org\/10.1111\/cen.13737","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"3595_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2967\/jnumed.118.211706","volume":"60","author":"S Han","year":"2019","unstructured":"S. Han, C.H. Suh, S. Woo et al. Performance of Ga-68-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med 60(3), 369\u2013376 (2019). https:\/\/doi.org\/10.2967\/jnumed.118.211706","journal-title":"J Nucl Med"},{"issue":"10","key":"3595_CR27","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","volume":"43","author":"I Janssen","year":"2016","unstructured":"I. Janssen, C.C. Chen, C.M. Millo et al. PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 43(10), 1784\u20131791 (2016). https:\/\/doi.org\/10.1007\/s00259-016-3357-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3595_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/jcb-199005","volume":"5","author":"V Seifert","year":"2019","unstructured":"V. Seifert, J. Liers, T. Kniess et al. Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization. J. Cell Biol. 5(2), 135\u2013151 (2019). https:\/\/doi.org\/10.3233\/jcb-199005","journal-title":"J. Cell Biol."},{"issue":"5","key":"3595_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00259-017-3896-9","volume":"45","author":"A Jha","year":"2018","unstructured":"A. Jha, A. Ling, C. Millo et al. Superiority of Ga-68-DOTATATE over F-18-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45(5), 787\u2013797 (2018). https:\/\/doi.org\/10.1007\/s00259-017-3896-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3595_CR30","doi-asserted-by":"publisher","first-page":"00053","DOI":"10.3389\/fonc.2019.00053","volume":"9","author":"A Jha","year":"2019","unstructured":"A. Jha, K. de Luna, C.A. Balili et al. Clinical, diagnostic, and treatment characteristics of sdha-related metastatic pheochromocytoma and paraganglioma. Front Oncol 9, 00053 (2019). https:\/\/doi.org\/10.3389\/fonc.2019.00053","journal-title":"Front Oncol"},{"issue":"4","key":"3595_CR31","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.esmoop.2021.100171","volume":"6","author":"S Severi","year":"2021","unstructured":"S. Severi, A. Bongiovanni, M. Ferrara et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open 6(4), 100171 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2021.100171","journal-title":"ESMO Open"},{"issue":"5","key":"3595_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11864-021-00834-3","volume":"22","author":"A Garcia-Alvarez","year":"2021","unstructured":"A. Garcia-Alvarez, J. Hernando Cubero, J. Capdevila, Drug development in neuroendocrine tumors: what is on the horizon? Curr Treat Options Oncol 22(5), 43 (2021). https:\/\/doi.org\/10.1007\/s11864-021-00834-3","journal-title":"Curr Treat Options Oncol"},{"key":"3595_CR33","doi-asserted-by":"publisher","unstructured":"M. L. Johnson, T. Meyer, D. M. Halperin, et al. First in human phase 1\/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results. J Clin Oncol. 36(15), (2018). https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.4097","DOI":"10.1200\/JCO.2018.36.15_suppl.4097"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03595-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T21:04:48Z","timestamp":1720904688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3595"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03595-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have given their information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All studies analyzed in the present study were in accordance with the Declaration of Helsinki and were approved by the Ethics Committee of Zhongshan Hospital, Fudan University.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}